Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110070 | 0.87 | QDPR (0.35) | QDPR | |
| SCHEMBL16790348 | 0.85 | QDPR (0.34) | QDPR | |
| SCHEMBL10841856 | 0.83 | QDPR (0.43) | QDPR | |
| SCHEMBL11946727 | 0.80 | MAOA (0.34) | — | |
| SCHEMBL9127421 | 0.79 | QDPR (0.37) | QDPR | |
| SCHEMBL9128228 | 0.79 | QDPR (0.37) | QDPR | |
| SCHEMBL24148714 | 0.77 | QDPR (0.35) | QDPR | |
| SCHEMBL15321417 | 0.77 | QDPR (0.39) | QDPR | |
| SCHEMBL863210 | 0.76 | — | — | |
| SCHEMBL840146 | 0.76 | KDM4E (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0325263-B1 | TETRAHYDROPYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM KG (DE) | 1992-09-23 | — | — | EP | claimed |
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024059041-A1 | BENZO-FUSED N-HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240018138-A1 | PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | VENTUS THERAPEUTICS U.S., INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018138-A1 | PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | VENTUS THERAPEUTICS U.S., INC. | 2024-01-18 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2023-11-07 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20080113950-A1 | Drugs for chronic pains | NICOX S.A. | 2008-05-15 | — | — | US | disclosed |
| US-7358251-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070161576-A1 | Drugs for chronic pains | NICOX S.A. | 2007-07-12 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-7199141-B2 | Drugs for chronic pains | NICOX S.A. (FR) | 2007-04-03 | — | — | US | disclosed |
| US-7199141-B2 | Drugs for chronic pains | NICOX S.A. (FR) | 2007-04-03 | — | — | US | disclosed |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | QDPR 1014/4885 |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | PRKDC, MAP3K20, MAP3K5 | QDPR 1119/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | QDPR 36/4885 |
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | QDPR 4622/4885 |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | QDPR 10/4885 |
| US-20080113950-A1 | Drugs for chronic pains | OPRD1, OPRL1, OPRK1 | QDPR 194/4885 |
| US-20070161576-A1 | Drugs for chronic pains | OPRD1, OPRL1, OPRK1 | QDPR 200/4885 |
| US-20240018138-A1 | PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | CGAS, LRRK2, ADSS2 | QDPR 3616/4885 |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | JAK2, JAK1, JAK3 | QDPR 657/4885 |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | QDPR 780/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | QDPR 3602/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | QDPR 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.